Important update for Pharmeasy investors
After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy.
Pharmeasy Consolidated Results (including all subsidiaries) as per March,2021
Total Revenue => ₹4,363.2 cr
Total Consolidated Loss (including all subsidiaries) => ₹1,548.5 cr
Total Debt on 30th June,2021 => ₹2,772.61 cr
This means on every 1 cr sale of medicine, lab tests (including all subsidiaries), company incur a loss of 35.49 Lacs.
People should be cautious while investing in Pharmeasy stocks at such steep valuations or exit before the stock crashes.